Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfgang Muster

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Chemical Research in Toxicology|December 21, 2019
Genotoxicity Assessment of Drug Metabolites in the Context of MIST and BeyondAndreas Zeller, Alessandro Brigo, Andreas Brink, et al.
Regulatory Toxicology and Pharmacology : RTP|October 15, 2020
Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updatesCatrin Hasselgren, Joel Bercu, Alex Cayley, et al.
Mutation Research|April 26, 2011
Suitable top concentration for tests with mammalian cells: mouse lymphoma assay workgroupMartha M Moore, Masamitsu Honma, Julie Clements, et al.
Regulatory Toxicology and Pharmacology : RTP|September 2, 2023
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessmentsAlex N Cayley, Robert S Foster, Alessandro Brigo, et al.
Regulatory Toxicology and Pharmacology : RTP|October 25, 2025
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugatesOsama Chahrour, Paul D Cornwell, Penny Leavitt, et al.
Frontiers in Toxicology|December 19, 2025
Retrospective analysis of clinical laboratory parameters in Han Wistar rat controlsRupert Kellner, Alexander Amberg, Frank Bringezu, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2019
Qualification of impurities based on metabolite dataLars Weidolf, Thomas Andersson, Joel P Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|February 11, 2012
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry surveyKrista L Dobo, Nigel Greene, Charlotta Fred, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum DisorderPatrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2015
Establishing best practise in the application of expert review of mutagenicity under ICH M7Chris Barber, Alexander Amberg, Laura Custer, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Chemical Research in Toxicology|December 21, 2019
Genotoxicity Assessment of Drug Metabolites in the Context of MIST and BeyondAndreas Zeller, Alessandro Brigo, Andreas Brink, et al.
Regulatory Toxicology and Pharmacology : RTP|October 15, 2020
Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updatesCatrin Hasselgren, Joel Bercu, Alex Cayley, et al.
Mutation Research|April 26, 2011
Suitable top concentration for tests with mammalian cells: mouse lymphoma assay workgroupMartha M Moore, Masamitsu Honma, Julie Clements, et al.
Regulatory Toxicology and Pharmacology : RTP|September 2, 2023
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessmentsAlex N Cayley, Robert S Foster, Alessandro Brigo, et al.
Regulatory Toxicology and Pharmacology : RTP|October 25, 2025
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugatesOsama Chahrour, Paul D Cornwell, Penny Leavitt, et al.
Frontiers in Toxicology|December 19, 2025
Retrospective analysis of clinical laboratory parameters in Han Wistar rat controlsRupert Kellner, Alexander Amberg, Frank Bringezu, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2019
Qualification of impurities based on metabolite dataLars Weidolf, Thomas Andersson, Joel P Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|February 11, 2012
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry surveyKrista L Dobo, Nigel Greene, Charlotta Fred, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum DisorderPatrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2015
Establishing best practise in the application of expert review of mutagenicity under ICH M7Chris Barber, Alexander Amberg, Laura Custer, et al.
Pageof 4